Drugs / F-18
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03386669 | Jul 2017 → Jul 2019 | parkinsonian disorder | Chang Gung Memorial Hospital | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-07-10 | CereMark Pharma, LLC | CereMark Pharma Begins Phase III Trial of F-18 Flornaptitril, a Novel Diagnostic Radiopharmaceutical Focused on Neurodegeneration ceremarkpharma.com ↗ |
| 2023-12-08 | CereMark Pharma, LLC | CereMark Pharma and Invicro to Collaborate on the Development of F-18 Flornaptitril ceremarkpharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | F-18 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03386669 ↗ |
| Modality | Diagnostic / imaging agent | “18F-THK5351 PET imaging as a biomarker and diagnostic tool” NCT03386669 ↗ |